NeuroPace (NPCE) says it remains on track to submit NAUTILUS data to the FDA for potential IGE indication expansion in the second half of 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- NeuroPace Appoints New CFO Amid Strategic Shift
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed